Navigation Links
Ferring to Highlight Phase 3 Data for Cervical Ripening Candidate at Society for Maternal-Fetal Medicine Annual Meeting
Date:2/12/2013

SAN FRANCISCO, Feb. 12, 2013 /PRNewswire/ -- Ferring Pharmaceuticals will present pivotal Phase 3 efficacy and safety data from its EXPEDITE* study for its investigational controlled release misoprostol vaginal insert (MVI) at the 33rd annual meeting of the Society for Maternal-Fetal Medicine (SMFM) in San Francisco, February 11 - 16. These and other research findings formed the basis for Ferring's New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) supporting the use of the controlled release MVI as a treatment option for cervical ripening as part of the labor induction process.

Studies accepted for presentation include

  • An oral presentation on Sat., Feb. 16 (9 a.m. – 9:15 a.m. PST), titled "Efficacy and safety of misoprostol vaginal insert compared with dinoprostone vaginal insert for labor induction" (lead author: Deborah A. Wing , MD, University of California, Irvine); and
  • A poster presentation on Thurs., Feb. 14 (3:30 p.m. – 5:30 p.m. PST), titled "Comparison of misoprostol vaginal insert and dinoprostone vaginal insert: incidence of treatment-emergent adverse events" (lead author: Stacey Ehrenberg-Buchner , MD, University of Michigan Health System).

*The EXPEDITE Study: A Phase 3, double blind, randomized, multicenter study of exogenous prostaglandin comparing the efficacy and safety of the misoprostol vaginal insert (MVI) 200 mcg to the dinoprostone vaginal insert for reducing time to vaginal delivery in pregnant women at term.

For further information, contact:
Leila Boukassi
MSL New York
leila.boukassi@mslgroup.com; 646.500.7735 

About Ferring Pharmaceuticals:
Ferring Pharmaceuticals is a research-driven speciality biopharmaceutical company, active in global markets. The company identifies, develops and markets innovative products in the areas of general and pediatric endocrinology, gastroenterology, infertility, obstetrics/gynecology, orthopedics and urology. For more information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.

 


'/>"/>
SOURCE Ferring Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ESTEVE Fosters R & D by Transferring its Center for Drug Discovery to the Science Park of Barcelona (PCB)
2. Ferring Pharmaceuticals Inc. Named 10th Fastest Growing New Jersey Company
3. Ferring Pharmaceuticals Inc. Recognized for Best-in-Class Work-Life Portfolio
4. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
5. Staffing and Performance Benchmarks for Quality Function Highlight New Medical Device Study
6. Isis Reports Financial Results and Highlights for First Quarter 2012
7. Delcath Highlights First Quarter 2012 And Recent Accomplishments
8. Soligenix Reports First Quarter 2012 Financial Results and Highlights Recent Accomplishments
9. Volcano to Highlight its Leadership in Precision Guided Therapy at EuroPCR 2012
10. "Emergency Medical Services Week" Highlights Stroke Survivors and Awareness
11. PharMEDium Highlights Enhanced Labeling for ICU Services at Critical Care Expo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016  Syneron Medical Ltd. (NASDAQ: ELOS ... today that William Griffing , Chief Executive ... to participate in the Leerink Partners 5 th ... 2016 in New York City ... meet with the Mr. Griffing and will include ...
(Date:2/5/2016)... 2016 http://www.researchandmarkets.com/research/jsc97m/global ... "Global Musculoskeletal Partnering 2010-2016: Deal trends, ... their offering. --> http://www.researchandmarkets.com/research/jsc97m/global ... "Global Musculoskeletal Partnering 2010-2016: Deal trends, ... their offering. --> Research ...
(Date:2/5/2016)... 2016  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... underwritten secondary offering of 11,027,558 shares of its common ... of Blackstone and Goldman Sachs.  The shares are being ... $96.45 per share. The selling stockholders will receive all ... nor any of its directors, officers or other stockholders ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure Dental Health ... in need. The event is scheduled to take place on February 27, 2016 from ... dental care to community members in need. Each patient will be given the opportunity ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... of CitiDent, announces that it is now welcoming orthodontist, Dr. Amanda Cheng, ... offers a complete range of oral health care, including general dentistry, cosmetic treatments, ...
(Date:2/5/2016)... , ... February 05, 2016 , ... In sleep, when ... as a dream. A hallmark feature of patients with eating disorders is significant self-criticism, ... eating disorder behaviors and obsessions are regarded as maladaptive means for coping with this ...
(Date:2/5/2016)... ... February 05, 2016 , ... California Mobile ... the debut of their latest mobile kitchen model, featuring customizable stainless steel interiors ... high-volume commercial kitchens for use anywhere in the U.S. Many of their units ...
(Date:2/5/2016)... ... , ... Calls Blacklist has just been updated by mobile app developer Vlad ... has fixed known bugs within the app. Calls Blacklist allows its users to only ... any of their device’s battery power or memory. It provides a powerful call blocker ...
Breaking Medicine News(10 mins):